1. Home
  2. ELA vs RLMD Comparison

ELA vs RLMD Comparison

Compare ELA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envela Corporation

ELA

Envela Corporation

HOLD

Current Price

$21.32

Market Cap

536.7M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$5.24

Market Cap

524.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELA
RLMD
Founded
1965
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.7M
524.9M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
ELA
RLMD
Price
$21.32
$5.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$16.50
$12.40
AVG Volume (30 Days)
123.8K
1.8M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
115.38
45.28
EPS
0.34
N/A
Revenue
$241,021,362.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
$22.54
N/A
P/E Ratio
$60.74
N/A
Revenue Growth
33.62
154.83
52 Week Low
$5.42
$0.55
52 Week High
$29.68
$8.00

Technical Indicators

Market Signals
Indicator
ELA
RLMD
Relative Strength Index (RSI) 36.49 34.95
Support Level $16.31 $4.06
Resistance Level $28.56 $7.28
Average True Range (ATR) 1.09 0.39
MACD -0.21 -0.08
Stochastic Oscillator 22.99 19.83

Price Performance

Historical Comparison
ELA
RLMD

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: